Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2004 February;56(1) > Minerva Pediatrica 2004 February;56(1):51-62

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA PEDIATRICA

A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532


eTOC

 

REVIEWS  


Minerva Pediatrica 2004 February;56(1):51-62

language: English

Recent developments and controversies in Kawasaki disease

Guzman-Cottrill J.A., Shulman S.T.


PDF  


In the developed world, Kawasaki disease is currently the leading cause of pediatric acquired heart disease. To date, the etiologic agent remains unknown. Many hypotheses regarding the etiology exist, and debate continues as to whether the inflammatory response of Kawasaki disease results from a superantigen or a conventional antigen. A variety of growth factors, proteinases, and cytokines have been identified that are involved in the pathogenesis of coronary artery disease in Kawasaki disease. These findings are leading to novel treatment strategies in Kawasaki disease, including platelet glycoprotein receptor inhibitors and monoclonal antibody to tumor necrosis factor-a. The role of corticosteroids remains controversial, and ongoing clinical trials are evaluating its efficacy. Additional studies have focused on newer non-invasive methods of evaluating children with coronary artery disease as alternatives to coronary catheterization. We review recent developments and controversies in exploring the etiology, pathogenesis, diagnosis, and management of Kawasaki disease.

top of page

Publication History

Cite this article as

Corresponding author e-mail